Evidence map›Paper›PMID 26971321›Full record

SynthesisInternational journal of epidemiology2016

Meta-analysis of genome-wide association studies reveals genetic overlap between Hodgkin lymphoma and multiple sclerosis.

Pouya Khankhanian, Wendy Cozen, Daniel S Himmelstein, Lohith Madireddy, Lennox Din, Anke van den Berg, Takuya Matsushita, Sally L Glaser, Jayaji M Moré, Karin E Smedby and 20 more

Open access · greenAbstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in International journal of epidemiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 3 pooled it
2.7field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 3 syntheses or guidelines pooled it, 28 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Novel Insights Into the Long-Term Immune Health of Diffuse Large B-Cell Lymphoma Survivors.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020
    Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors at 17 institutions in 11 countries.

Pouya KhankhanianCenter for Neuroengineering and Thereapeutics at the University of Pennsylvania, Philadelphia, PA, USA University of California, San Francisco, CA, USA.
Wendy CozenUniversity of Southern California, Los Angeles, CA, USA.
Daniel S HimmelsteinUniversity of California, San Francisco, CA, USA.
Lohith MadireddyUniversity of California, San Francisco, CA, USA.
Lennox DinUniversity of California, San Francisco, CA, USA.
Anke van den BergUniversity Medical Center, Groningen, The Netherlands.
Takuya MatsushitaUniversity of California, San Francisco, CA, USA.
Sally L GlaserCancer Prevention Institute of California, Fremont, CA, USA.
Jayaji M MoréUniversity of California, San Francisco, CA, USA.
Karin E SmedbyKarolinska Institute, Stockholm, Sweden.
Sergio E BaranziniUniversity of California, San Francisco, CA, USA.
Thomas M MackUniversity of Southern California, Los Angeles, CA, USA.
Antoine LizéeUniversity of California, San Francisco, CA, USA.
Silvia de SanjoséCatalan Institute of Oncology, L'Hospitalet de Llobregat, Catalonia, Spain.
Pierre-Antoine GourraudUniversity of California, San Francisco, CA, USA.
Alexandra NietersUniversity Medical Center Freiburg, Freiburg, Germany.
Stephen L HauserUniversity of California, San Francisco, CA, USA.
Pierluigi CoccoUniversity of Cagliari, Cagliari, Sardinia, Italy.
Marc MaynadiéCentre Hospitalier Universitaire de Dijon, Dijon, France.
Lenka ForetováMasaryk Memorial Cancer Institute, Brno, Czech Republic.
Anthony StainesUniversity College Dublin, Dublin, Ireland.
Manon Delahaye-SourdeixInternational Agency for Research on Cancer, Lyon, France.
Dalin LiUniversity of Southern California, Los Angeles, CA, USA.
Smita BhatiaCity of Hope National Medical Center, Duarte, CA, USA.
Mads MelbyeStatens Serum Institut, Copenhagen S, Denmark.
Kenan OnelUniversity of Chicago, Chicago, IL, USA.
Ruth JarrettMRC, University of Glasgow Centre for Virus Research, Glasgow, UK.
James D McKayInternational Agency for Research on Cancer, Lyon, France.
Jorge R OksenbergUniversity of California, San Francisco, CA, USA.
Henrik HjalgrimStatens Serum Institut, Copenhagen S, Denmark HHJ@ssi.dk.
University of California, San Francisco · USUniversity of Southern California · USCentre International de Recherche sur le Cancer · FRStatens Serum Institut · DKCancer Prevention Institute of California · USCentre Hospitalier Universitaire Dijon Bourgogne · FRCity Of Hope National Medical Center · USInstitut Català d'Oncologia · ESKarolinska Institutet · SEMasaryk Memorial Cancer Institute · CZMRC University of Glasgow Centre for Virus Research · GBUniversity College Dublin · IEUniversity Medical Center Freiburg · DEUniversity Medical Center Groningen · NLUniversity of Cagliari · ITUniversity of Chicago · USUniversity of Pennsylvania · US

Funding

Mach-LETSGO: Machine-LEarning of Treatment, Survey, and Genetics towards Obtaining Correct Classification of Chronic Conditions in Adult Survivors in the Childhood Cancer Survivor Study - CCSS SupplU24CA055727 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Gregory Armstrong · 1999 to 2026
$96.7M
WS No. 10 Patterns of Care DX Year 2007N01PC35136 · NCI · CANCER PREVENTION INSTIT OF CALIFORNIA · PI GLASER, SALLY L · 2007 to 2009
$9.3M
WS No. 9 Health Eating Activity and Lifestyle StudyN01PC35139 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI DEAPEN, DENNIS M. · 2007 to 2010
$8.6M
GENE LINKAGE STUDY OF MULTIPLE SCLEROSIS SIBLING PAIRSR01NS026799 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HAUSER, STEPHEN L, OKSENBERG, JORGE R. · 1989 to 2018
$6.8M
NINDS Research Education Programs for Residents and Fellows in Neurology, Neurosurgery, Neuropathology, Neuroradiology and Emergency Medicine (R25)R25NS070680 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JOSEPHSON, SCOTT ANDREW · 2010 to 2023
$6.8M
BMI Bioinformatics Training GrantsT32GM067547 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HERNANDEZ, RYAN D. · 2003 to 2022
$6.6M
Integrative Program in Complex Biological System (ipCBS)T32EB009383 · NIBIB · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MARSHALL, WALLACE, WEINER, ORION D · 2009 to 2022
$3.2M
Medical Research Council MC_UU_12014/3NCI NIH HHS N01PC35136NCI NIH HHS N01PC35139NCI NIH HHS U24 CA055727NIBIB NIH HHS T32 EB009383NIGMS NIH HHS T32 GM067547NINDS NIH HHS R01 NS026799NINDS NIH HHS R25 NS070680Wellcome TrustWorld Health Organization 001
6 · The paper itself

Abstract

backgroundBased on epidemiological commonalities, multiple sclerosis (MS) and Hodgkin lymphoma (HL), two clinically distinct conditions, have long been suspected to be aetiologically related. MS and HL occur in roughly the same age groups, both are associated with Epstein-Barr virus infection and ultraviolet (UV) light exposure, and they cluster mutually in families (though not in individuals). We speculated if in addition to sharing environmental risk factors, MS and HL were also genetically related. Using data from genome-wide association studies (GWAS) of 1816 HL patients, 9772 MS patients and 25 255 controls, we therefore investigated the genetic overlap between the two diseases.

methodsFrom among a common denominator of 404 K single nucleotide polymorphisms (SNPs) studied, we identified SNPs and human leukocyte antigen (HLA) alleles independently associated with both diseases. Next, we assessed the cumulative genome-wide effect of MS-associated SNPs on HL and of HL-associated SNPs on MS. To provide an interpretational frame of reference, we used data from published GWAS to create a genetic network of diseases within which we analysed proximity of HL and MS to autoimmune diseases and haematological and non-haematological malignancies.

resultsSNP analyses revealed genome-wide overlap between HL and MS, most prominently in the HLA region. Polygenic HL risk scores explained 4.44% of HL risk (Nagelkerke R(2)), but also 2.36% of MS risk. Conversely, polygenic MS risk scores explained 8.08% of MS risk and 1.94% of HL risk. In the genetic disease network, HL was closer to autoimmune diseases than to solid cancers.

conclusionsHL displays considerable genetic overlap with MS and other autoimmune diseases.

Indexed as

Genome-Wide Association StudyPolymorphism, Single NucleotideFemaleGene Regulatory NetworksGenetic Predisposition to DiseaseHodgkin DiseaseHumansLinear ModelsMaleMultiple Sclerosis

Identifiers

PMID26971321
PMCPMC5005944
OpenAlexW2310337733

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.